XNASADIL
Market cap6mUSD
Dec 26, Last price
1.05USD
1D
0.00%
1Q
3.96%
IPO
-98.95%
Name
Adial Pharmaceuticals Inc
Chart & Performance
Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 6,889 | 13,378 | 17,795 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (6,889) | (13,378) | (17,795) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (502) | (94) | |||||||
Tax Rate | |||||||||
NOPAT | (6,889) | (13,377) | (17,701) | ||||||
Net income | (7,002) -45.00% | (12,731) -34.45% | (19,423) 78.84% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,132 | 9,126 | 11,750 | ||||||
BB yield | -155.94% | -4,238.11% | -23.41% | ||||||
Debt | |||||||||
Debt current | 57 | 50 | |||||||
Long-term debt | 358 | 464 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | (437) | 492 | 1,014 | ||||||
Net debt | (4,361) | (2,986) | (4,934) | ||||||
Cash flow | |||||||||
Cash from operating activities | (6,807) | (11,186) | (11,949) | ||||||
CAPEX | (65) | ||||||||
Cash from investing activities | 1,500 | (34) | |||||||
Cash from financing activities | 4,132 | 9,126 | 13,645 | ||||||
FCF | (6,644) | (13,317) | (18,006) | ||||||
Balance | |||||||||
Cash | 2,827 | 4,002 | 6,062 | ||||||
Long term investments | 1,534 | (601) | (614) | ||||||
Excess cash | 4,361 | 3,401 | 5,448 | ||||||
Stockholders' equity | (68,796) | (63,648) | (50,922) | ||||||
Invested Capital | 72,879 | 67,624 | 55,701 | ||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 1,425 | 40 | 744 | ||||||
Price | 1.86 -65.40% | 5.38 -92.04% | 67.50 58.82% | ||||||
Market cap | 2,650 1,130.65% | 215 -99.57% | 50,190 136.88% | ||||||
EV | (1,711) | (2,771) | 45,255 | ||||||
EBITDA | (6,888) | (13,317) | (17,740) | ||||||
EV/EBITDA | 0.25 | 0.21 | |||||||
Interest | 585 | ||||||||
Interest/NOPBT |